Cencora, Inc.
Healthcare Distribution and Specialty PharmacyFounded 1985- Updated June 2026
Reviewed by Swet Parvadiya
Last reviewed: June 2026
CorpDigest
Cencora, Inc.
Company History
Founded 1985 in Conshohocken, Pennsylvania
Last reviewed: 2026-06-08 · By Swet Parvadiya
Cencora, Inc. generated $278.0 billion in FY2024 global revenue, operating as the foundational infrastructure of the US pharmaceutical supply chain and a rapidly expanding global commercialization powerhouse that commands a 3.0% gross margin by focusing exclusively on high-volume, low-margin wholesale distribution and higher-margin specialty logistics. The company's strategic identity was defined through the 2023 rebranding from AmerisourceBergen to Cencora, a massive corporate pivot that eliminated the legacy branding and permanently removed the stigma of the opioid litigation era to focus on the future of biotech commercialization and specialty pharmacy. This pivot has resulted in a highly diversified portfolio where growth is now being driven by the rapid scaling of next-generation assets, including the World Courier global clinical logistics network and the Alto Pharmacy specialty network. With approximately 43,000 employees and a market capitalization of $50 billion, Cencora allocates billions annually to operational optimization and strategic acquisitions, funding a pipeline of over 50 service expansions and enabling aggressive acquisitions in the specialty and logistics spaces. The company's future depends on its ability to execute a 4-6% constant currency sales CAGR through 2030, a target that requires the successful commercial launch of its cell and gene therapy logistics services and the continuous expansion of its dominant position in the US drug supply chain to offset the impending margin compression of its core wholesale distribution business and the relentless financial pressure of the $6.4 billion opioid settlement.
Steven H. Collis is an American business executive who served as the CEO of AmerisourceBergen (now Cencora) from 2001 until his retirement in early 2024. He played a pivotal role in the company's survival during the early 2000s integration crisis, navigating the massive debt load and operational inefficiencies of the Bergen Brunswig merger to transform the company into the second-largest pharmaceutical distributor in the world. Collis's background in operations and supply chain management gave him a unique perspective on the pharmaceutical industry, driving his focus on operational excellence, specialty pharmacy integration, and global logistics expansion. During his tenure, he oversaw the acquisition of over 50 companies, including World Courier, Healthcare Solutions, and Alto Pharmacy, which generated tens of billions of dollars in cumulative revenue and transformed the company from a traditional wholesale distributor into a diversified healthcare services platform. Collis was also known for his aggressive capital allocation strategy, which prioritized share repurchases and dividend growth while simultaneously managing the massive financial burden of the opioid litigation settlement. Despite the controversy surrounding the opioid crisis, Collis is widely credited with transforming Cencora from a struggling, low-margin distributor into a global healthcare services powerhouse, although his legacy is permanently intertwined with the regulatory and reputational challenges of the pharmaceutical supply chain.
The corporate lineage of Cencora began with the founding of Chemsource in Pennsylvania, initially focusing on the distribution of generic pharmaceuticals and animal health products.
Steven H. Collis orchestrated a series of aggressive acquisitions that transformed Chemsource into Amerisource Health, establishing a foothold in the national pharmaceutical distribution market.
Amerisource Health merged with Bergen Brunswig to form AmerisourceBergen, creating the second-largest pharmaceutical distributor in the United States and triggering a massive operational integration challenge.
CEO Steven H. Collis executed a brutal operational overhaul, slashing costs, unifying IT systems, and pivoting the company toward specialty distribution, saving the company from bankruptcy.
AmerisourceBergen acquired World Courier, establishing a dominant position in the global clinical logistics market and laying the foundation for the future Global Commercialization and Services segment.
The company launched Alto Pharmacy, a national specialty pharmacy network designed to capture the highest-margin segments of the drug supply chain and improve patient adherence.
Cencora, along with McKesson and Cardinal Health, agreed to a combined $21 billion national opioid settlement, with Cencora's share totaling approximately $6.4 billion to be paid through 2038.
AmerisourceBergen officially changed its name to Cencora, attempting to distance the corporate identity from the legacy wholesale distribution era and the stigma of the opioid litigation.
Cencora reported $278.0 billion in global revenue for FY2024, with operating income reaching $3.5 billion and free cash flow at $4.5 billion, demonstrating strong performance post-rebrand.
Cencora acquired Alto Pharmacy to establish a national specialty pharmacy network designed to capture the highest-margin segments of the drug supply chain and improve patient adherence.
Cencora acquired World Courier to establish a dominant position in the global clinical logistics market and lay the foundation for the future Global Commercialization and Services segment.
Cencora acquired Healthcare Solutions to secure a leading group purchasing organization (GPO) platform and expand its presence in the alternate care site market.